Abstract: Symptomatic uterine fibroids are a relatively common gynecologic condition. In the past, fibroids were exclusively treated by myomectomy and/or hysterectomy. With the advent of uterine artery embolization or uterine artery occlusion, there now exist minimally invasive approaches to fibroid therapy especially for women in whom surgery is contraindicated or for those who wish to retain their uterus and possibly fertility. Fertility and pregnancy outcomes after these minimally invasive therapies are currently being evaluated.
Introduction
Uterine fibroids are the most common solid pelvic tumors in women, typically reported to occurr in 20% to 40% of reproductive aged women 1, 2 and up to 70% of white and 80% of women of African ancestry by the age of 50. 2 Although most fibroids are asymptomatic, uterine fibroids are listed as the indication for 40% to 50% of hysterectomies performed. 1, 3, 4 Current philosophy and practice of health care providers has shifted to exploring alternative therapies for fibroids including medical treatment, myomectomy, myolysis, and, most recently, uterine artery occlusion (UAO) by transfemoral embolization, laparoscopic occlusion, or transvaginal temporary occlusion guided by Doppler.
Transcatheter Uterine Artery Embolization

HISTORICAL
Transcatheter uterine artery embolization (UAE) was originally used in obstretics in 1979 to control persistent massive postpartum hemorrhage after failure of bilateral surgical ligation of the hypogastric arteries. 5 The same procedure was introduced by Ravina et al 6 in 1994, as a primary treatment of uterine fibroids. Subsequently, it was introduced in the United States in 1997, and Canada in 1998.
PATIENT ASSESSMENT
All women should be counseled in accordance with established clinical practice guidelines before undergoing UAE. 7 Physicians and patients should understand that UAE is a relatively new procedure (less than 10 years old) and is associated with potential side effects and complications. The long-term effects and durability of UAE are not yet known. Recommended preoperative evaluation tests are included in Table 1 , whereas contraindications to UAE are included in Table 2 .
PROCEDURE
The treatment is performed in a medical imaging suite by interventional radiologists using aseptic techniques and sterile conditions. Using conscious sedation and local analgesia, a 5F catheter is inserted into the right femoral artery. Some centers perform the procedure under spinal or epidural analgesia.
First, a mapping angiogram is performed using a radio-opaque contrast to identify the vessels. Once the desired artery is located, the catheter is threaded into its lumen under fluoroscopic guidance and a variety of embolic agents are injected until the flow becomes sluggish.
Options for embolic material include polyvinyl alcohol (PVA) particles, trisacryl gelatin microspheres, gelfoam pledgets, or metal coils.
SIDE EFFECTS AND COMPLICATIONS
Perioperative risks and complications of UAE include bleeding and hematomas at the groin femoral artery puncture site, allergic or anaphylactic reactions to the iodinated contrast dye, incomplete uterine artery access, missembolization of nontarget organs, and severe pain. These complications occur approximately in 1% to 2% of all procedures. Virtually all women experience some degree of acute, crampy pain thought to be due to ischemia of the uterus and fibroids, requiring regional analgesia and/or opiates and nonsteroidal anti-inflammatory drugs. 8 No correlation has been established between uterine size, myoma number or size, duration of procedure, or quantity of PVA particles used and clinical outcomes of the treatment. Worthington-Kirsch and Koller 9 reported the 24-hour course of pain after UAE, using hourly morphine injections as a surrogate for pain symptoms. Pain begins shortly after embolic occlusion of the second uterine artery, increases in severity over 2 hours, remains at a high plateau for 3 to 4 hours, and decreases 4 to 5 hours after the plateau. During the next 24 hours, the pain gradually decreases and most women are discharged home. Up to 40% of women may experience a constellation of signs and symptoms after UAE including diffuse abdominal pain, generalized malaise, anorexia, nausea, vomiting, low-grade fever and leukocytosis. Post-UAE syndrome is self-limiting and usually resolves in a few days with supportive therapy (hydration and nonsteroidal anti-inflammatory drugs). 8 Cases of transient unilateral buttock pain and sciatica with foot drop have also been observed. Spies and colleagues 10 reported on complications in 400 consecutive UAE in a single institution; 10 in-hospital and an additional 27 postdischarge complications within the first 30 days. Thirty-four patients experienced a periprocedural complication, rate of 8.5%, and 5 were serious complications. There were no deaths, no major permanent injuries and overall morbidity was 5%. Isolated cases of pyometria, salpingitis, tubo-ovarian abscess, infected myomas, sepsis, disseminated intravascular coagulation and death have been reported after UAE. In addition, necrosis of the uterus, cervix, upper vagina, labia, bladder, ureters and buttocks, vault necrosis with bladder fistula and also cases of inadvertent embolization of leiomyosarcomas, endometrial cancer, and ovarian cancer have also been reported.
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Within 3 months after UAE, spontaneous expulsion of myomas may occur in up to 18% of patients. In women with submucous myoma confirmed hysteroscopically, 60% passed myoma vaginally.
UAE CLINICAL OUTCOMES
Clinical outcomes after UAE include changes in menstruation and bulk effects from fibroids, and also avoidance of subsequent gynecologic surgical intervention.
In 12 At 3 months, menstrual bleeding and bulk symptoms improved in 87% and 93% of women, respectively. At 12 months, the corresponding improvements were 90% and 91%, respectively. The authors also reported that 10.5% of women required further gynecologic intervention, with 4.5% of women having a hysterectomy at 14 to 32 weeks after UAE. 12 In 2002, Walker and Pelage 13 reported on 400 women treated by UAE in a single centre in the UK. In 395 women (98.8%), both uterine arteries were successfully occluded. At a mean follow-up of 16.7 months, menstrual bleeding improved in 84% of women and menstrual pain improved in 79%. Ultrasound measurements indicated significant reduction in the mean uterine and dominant fibroid volume of 55% and 73%, respectively (P = 0.001) and by magnetic resonance imaging (MRI) 53% and 64%, respectively. Twelve women (3%) required hysterectomy; 3 for an infective process, and 9 for clinical failure. Twenty-six women (7%) developed amenorrhea by 4 to 18 months after UAE
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Vilos et al including 4 patients under the age of 45 (2%). Ninety-seven percent of women were pleased with the outcome. The authors concluded that UAE is associated with a high clinical success rate and good fibroid volume reduction. 13 In 2003, Pron and associates 14 reported on 555 women from a Canadian, multicenter, clinical trial. UAE was accomplished bilaterally in 538 (97%) women, unilaterally in 14 (2.5%) and was unsuccessful in 3 (0.5%) women. Follow-up ultrasound at 3 months showed a mean uterine and dominant fibroid volume reduction of 35% and 42%, respectively. Heavy menstrual bleeding, dysmenorrhea, and urinary frequency were improved in 83%, 77%, and 86% of women, respectively, whereas mean menstrual duration decreased from 7.6 to 5.4 days. Improvements in heavy menstrual bleeding were unrelated to pre-UAE uterine size or post-UAE uterine volume reduction. Secondary amenorrhea was highly agedependent; encountered in only 3% of women under 40 and in 41% of women over 50 years of age. There were 8 (1.5%) hysterectomies; 2 for infection, 4 for pain, 1 for prolapsed fibroid and 1 for persistent bleeding. Ninety-one percent of women were satisfied with the treatment. 14 In 1999, the Society of Interventional Radiology Foundation developed the Fibroid Registry for Outcomes Data (FIBROID). 15 As of December 31, 2002, 3319 UAE cases had been entered into the registry by 72 sites. Heavy menstrual bleeding was the single most bothersome symptom in 64.3% of patients. Technical success was achieved in 96.2% of patients. Of the 3160 evaluable patients, there were 0.66% major inhospital complications and 4.8% postdischarge major events, occurring within 30 days. The most common adverse event after discharge was pain-requiring rehospitalization (2.4%). Thirty-one patients required additional surgical intervention, with 3 requiring hysterectomy (0.1%). There were no deaths. Multivariate analysis showed modest increased odds for an adverse event for African Americans, smokers, and those with prior leiomyoma procedures. The authors concluded that UAE is a low risk procedure with little variability in short-term outcome based on either patient demographics or practice setting. 15, 16 Follow-up data were obtained on 1797 of these women (85.1%) at 6 months and 1701 women (80.5%) at 12 months after embolization. 17 At 12 months, the mean symptom score had improved by 67% (from 58.61 to 19.23, P<0.001), whereas 5.5% of patients had no improvement. The mean health-related quality-of-life score improved by 46% (from 46.95 to 86.68, P<0.001) in 95% of women. In the first year after UAE, hysterectomy was performed in 2.9% of patients, with 3.6% requiring gynecologic interventions by 6 months and an additional 5.9% between 6 and 12 months. Amenorrhea after embolization occurred in 7.3% of patients. Of these women, 86% were aged 45 years or older. Predictors of an improved clinical outcome included smaller fibroid size, submucosal location, and heavy bleeding. Most patients (82%) were satisfied with their results. The authors concluded that UAE resulted in substantial symptom improvement in most patients. 17 In general, UAE is feasible in 96% to 99% of women with fibroids. After approximately 12 months of follow-up, menstrual bleeding improved in 80% to 90% of women and uterine or fibroid volume is reduced by 40% to 50%. Up to 80% to 90% of women are satisfied with their clinical outcome. Addition of a gonadotropin releasing hormone agonist, (goserelin acetate 10.8 mg) within 24 hours after UAE does not alter the rate and volume of reduction of symptomatic uterine myomas.
A Canadian retrospective review of 545 women with uterine fibroids indicated that UAE was associated with lower hospital cost and shorter hospital stay compared with abdominal myomectomy, abdominal hysterectomy, or vaginal hysterectomy. 19 A randomized clinical trial also demonstrated that UAE is safe and effective for the treatment of symptomatic fibroids, is associated with a shorter hospital stay and results in fewer major complications compared to abdominal hysterectomy. 20 In the most comprehensive and longest term followup of a large cohort of treated women, Spies and colleagues 21 reported that 72% of women having UAE continued to have improved clinical outcome up to 5 years after the initial procedure.
FERTILITY AND PREGNANCY OUTCOMES AFTER UAE
Serious concerns have been raised about the potential effects of UAE on fertility and pregnancy outcomes. Histopathology shows UAE has a sparing effect on myometrium. There have been case reports of uterine necrosis and PVA particles located within the myometrium. Consequently, uterine wall integrity and strength after UAE remains unknown. Endometrial atrophy and permanent amenorrhea, in the presence of normal serum follicle stimulating hormone and estradiol levels, have also been reported after UAE. These differences in patient populations may account for the differences seen in pregnancy outcomes. 22 Pron and associates 23 reported 24 pregnancies in 21 women from a population of 538 women treated with UAE for symptomatic fibroids (The Ontario Multicentre Trial). The clinical outcomes did not differ from those reported in the general population. Two cases developed placenta previa and one placenta accreta, resulting in cesarean hysterectomy. The authors concluded that women are able to conceive after UAE and most of these pregnancies resulted in term deliveries of appropriately grown newborns. 23 Carpenter and Walker 24 reported 29 pregnancies in 24 women from a group of 671 women treated with UAE in UK. Other than an increased cesarean section rate (88%), there did not appear to be any other major excess obstetric associated risk. 24 Although the number of pregnancies after UAE is low, it seems that embolization may not be associated with adverse pregnancy outcomes. The ACOG Committee Opinion (No. 293, February 2004) on UAE states: ''the procedure should be considered investigational or relatively contraindicated in women wishing to retain fertility.'' The Society of Obstetricians and Gynecologists of Canada Clinical Practice Guidelines state: ''UAE as a treatment for fibroids in patients
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Vilos et al wishing to preserve their fertility should be undertaken with full disclosure to the patient about the limitations of such a procedure and the lack of existing data regarding future fertility and pregnancy outcomes (III-C).'' 7
MECHANISM OF ACTION OF UAE
The uterus receives its blood supply mainly from the uterine arteries, and, as a result, uterine fibroids derive their blood supply almost totally from the uterine arteries. To explain the mechanism of action of UAE on fibroid death, Ravina and colleagues 6 theorized that embolic particles flowed selectively from the catheter tip in the uterine arteries to the arteries supplying the myoma, bypassing myometrial arteries along the way. This explanation propagated the concept that the particles were not only responsible but necessary for the successful treatment of fibroids. However, the equally effective treatment of symptomatic fibroids by UAO (see below), without particles, raised serious doubts about the mechanism of embolotherapy and, indeed, the need for the use of particles. Furthermore, serious concerns have been raised about potential side effects and complications of embolization that are directly related to the particles themselves.
UAO TRANSCATHETER UAO
The uterine arteries can be focally occluded by interventional radiologists using metal coils or gelatin sponges (Gelfoam pledgets, Pharmacia and Upjohn, Kalamazoo, MI). Gelatin sponges are temporary occluding agents, and allow recanalization of the uterine arteries once the fibroid has infarcted. Theoretically, gelatin sponges would better preserve fertility after UAO. However, at present, there are no published data supporting this assertion since only a few cases have been reported comparing UAE with UAO in women with fibroids. In 1 study of 18 patients the uterine and myoma volume decreased by 45% and 50%, respectively 12 months after UAO with gelatin sponges. 25 
LAPAROSCOPIC UAO
In 1999, Lee and colleagues 26 reported on the feasibility and preliminary results of laparoscopic uterine artery ligation in 62 women for primary treatment of symptomatic uterine fibroids. The average reduction of dominant fibroid volume was 54%. Liu and associates 27 reported that laparoscopic bipolar coagulation of uterine vessels was technically feasible in 97.7% (85/87) of women with symptomatic uterine fibroids. At a mean follow-up interval of 10.2 months, symptomatic improvement was reported in 89.4% of women, including 21.2% with complete resolution of symptoms. Using measurements derived from ultrasound evaluations, uterine and dominant fibroid volume reduced by an average of 46% (range 27% to 78%) and 76% (range 38% to 100%), respectively. Two patients conceived at 4 and 9 months after treatment (outcome not provided) and 3 (3.5%) women over the age of 45 years became menopausal. More favorable results occurred in women with fibroids greater than 5 cm diameter, where the average volume reduction was 86% versus 63% for fibroids less than 5 cm diameter. 27 Yen and colleagues 28 reported on laparoscopic bilateral coagulation of uterine and utero-ovarian arteries in 46 women with symptomatic fibroids. 28 At 6 months follow-up, heavy menstrual bleeding, dysmenorrhea, and bulk related symptoms improved 71.7%, 56.5%, and 38.7%, respectively. They also observed a reduction in uterine and dominant fibroid volume of 38.3% and 59.1%, respectively.
In 2002, Lichtinger and associates 29 reported on laparoscopic UAO in women, 6 by ligature and 2 by vascular clips, with symptomatic leiomyomas. Symptomatic improvement was reported by all patients. Istre and colleagues 30 reported on laparoscopic UAO by clips and concomitant bipolar desiccation by radiofrequency of the ovarian ligament in 15 women with symptomatic leiomyomata. After 6 months, there was an average reduction in myoma size of 44%. 30 These preliminary studies clearly demonstrated that particles are not needed for the treatment of uterine fibroids.
Park and associates 31 compared patients after UAE (23) with laparoscopic UAO with vascular clips (17) . At 6 months, the total mass volume reduction was 58.5% for the UAE and 56.0% for the laparoscopic occlusion groups, respectively. 31 The corresponding menstrual reduction scores were 87.6% and 60.9%, respectively. Immunocytochemical staining of specimens obtained by biopsy suggested that laparoscopic uterine artery ligation results mainly in physiologic cell death (apoptosis), whereas UAE causes cell necrosis. Perioperative complications included fever (15%), pain (30%), and bleeding (54%) in the UAE group and only bleeding (20%) in the laparoscopic occlusion group. 31 Hald and colleagues 32 compared 24 women undergoing UAE with 22 having laparoscopic UAO in a prospective parallel cohort study. 32 UAE was achieved bilaterally in 22 (92%) and unilaterally in 1 patient. Pain after laparoscopic occlusion, determined by visual analogue scores and pain control requirements, was significantly less (P = 0.008) than after UAE. At 3 to 6 months, average menstrual reduction scores were 63% to 66% and 50% in the UAE and laparoscopic occlusion groups, respectively. Two hysterectomies were performed; one because of lack of effect in the laparoscopy group and the other for a necrotic uterus in the UAE group. At 6 months, the average uterine and dominant fibroid volumes, measured by MRI, were reduced by 40% and 45% in the UAE, respectively and 36% and 37% in the laparoscopic occlusion group, respectively. 32 The preliminary evidence suggests that laparoscopic occlusion of uterine arteries in women with symptomatic fibroids is feasible and safe. UAO results in less postoperative pain, absence of post-UAE syndrome, and is equally efficacious to UAE in reducing myoma related symptoms. However, general application of laparoscopic UAO is limited by 2 major factors; first, laparoscopy carries its own inherent risks and complications and secondly, identification and occlusion of the uterine arteries requires surgical expertise and skills beyond the training and capability of the average gynecologist.
MECHANISM OF ACTION OF UAO
As a rule, the uterus is more vascular and better perfused than myomas themselves. After UAE, contrast-enhanced MR indicates loss of both uterine and myoma perfusion. Within hours of embolization, the uterus appears reperfused while fibroids show lack of perfusion. Burbank 33 proposed that after UAO, by any means, both the uterine and myoma vessels occlude by clotting resulting in organ ischemia. After a few hours, the uterus initiates fibrinolysis to lyse its own clots, and reperfusion begins. Fibroids do not initiate fibrinolysis which results in prolonged ischemia and fibroid death (Fig. 1) . 8, 33 Burbank and associates postulated that the response difference between myometrium and myomas may be due to synergistic effects of vascular density and coagulation/fibrinolysis differences between the two. 34 To test the above hypothesis, Lichtinger and associates 34 studied the minutes (T 3 , range 20 to 600 min). The pH returned to base line in 46%, 70%, 80%, and 95% of patients at 2, 4, 6, and 8 hours of UAO, respectively (Fig. 2) . 34 It is of interest to note that the general shape of the pain curve reported by Worthington-Kirsch and Koller 9 is a mirror image of the time course of uterine pH change after laparoscopic occlusion of the uterine arteries. 34 The uterus escaped ischemia within 6 hours of UAO in 80% of women. 34 These observations question the need to permanently occlude the uterine arteries. As a result, Burbank theorized that temporary UAO for a period of 6 hours should be as effective as UAE or permanent laparoscopic UAO for the treatment of symptomatic fibroids.
TRANSVAGINAL TEMPORARY UTERINE OCCLUSION
The uterine arteries are located less than 2 cm away from the vaginal fornices. A nonsurgical device has been designed for bilateral detection and temporary occlusion of the uterine arteries (flostat, Vascular Control Systems, San Juan Capistrano, CA). The components of the system are shown in Figure 3 .
Preliminary studies in Norway, 35 Mexico, 36 Canada, 37 and Florida 38 demonstrated its feasibility, safety, and short-term efficacy. A total of 75 women have participated in 5 (pilot) feasibility studies. Overall, a minimal number of minor adverse events were observed. These events included lower urinary tract infection, back pain, suprapubic pressure, and urgency, dysmenorrhea, and mild transient hydronephrosis. Two of 75 women (2.6%) developed hydronephrosis requiring temporary stenting. To mitigate the incidence of hydronephrosis, procedural changes were introduced including preoperative patient hydration, application of the flostat clamp before catheterization of the bladder and monitoring of urine output postoperatively. Follow-up MRI at 6 months showed 41 of 51 women (80%) had reduction in uterine volume. Six-month follow-up data from 1 pilot study (n = 13), using ultrasound and MRI, showed mean reduction of uterine and dominant fibroid volume of 24% and 45%, respectively (Fig. 4) . All 13 women (100%) reported bleeding symptom reduction using the Ruta Menorrhagia Severity Scale with an average change of -42% and there were no reports of amenorrhea.
From these preliminary results, it is reasonable to conclude that the Transvaginal Temporary Doppler Clamp (flostat) provides another alternative for minimally-invasive fibroid treatment. It is a global treatment for fibroids that can be used multiple times, for recurrent fibroids, and requires minimal training and surgical expertise.
Summary
UAO, by any method, is a safe and effective alternative to myomectomy or hysterectomy in women with uterine fibroids.
The equally effective treatment of symptomatic fibroids by UAO, without particles, and the serious complications attributed to the particles question the need for particles as agents for blocking the uterine artery blood flow.
UAO has been found to significantly reduce heavy menstrual bleeding, dysmenorrhea, and fibroid bulk-related effects in approximately 80% to 90% of women and 80% to 90% of women are satisfied with the treatment.
Although there is a reduction of 40% to 50% in total uterine and myoma volume within 6 months after embolization, long-term data are lacking.
